Literature DB >> 31326234

Treatable clinical intervention targets for patients with schizophrenia.

Daniel Freeman1, Kathryn M Taylor2, Andrew Molodynski2, Felicity Waite2.   

Abstract

BACKGROUND: Treatment approaches for patients with psychosis need major improvement. Our approach to improvement is twofold: target putative causal mechanisms for psychotic experiences that are treatable and also that patients wish treated. This leads to greater treatment engagement and clinical benefit. To inform mental health service provision we assessed the presence of treatable causal mechanisms and patient treatment preferences.
METHODS: Patients with non-affective psychosis attending NHS mental health services completed assessments of paranoia, hallucinations, anxious avoidance, worry, self-esteem, insomnia, analytic reasoning, psychological well-being, and treatment preferences.
RESULTS: 1809 patients participated. Severe paranoia was present in 53.4% and frequent voices in 48.2%. Of the causal mechanisms, severe worry was present in 67.7%, avoidance at agoraphobic levels in 64.5%, analytic reasoning difficulties in 55.9%, insomnia in 50.1%, poor psychological well-being in 44.3%, strongly negative self-beliefs in 36.6%, and weak positive self-beliefs in 19.2%. Treatment target preferences were: feeling happier (63.2%), worrying less (63.1%), increasing self-confidence (62.1%), increasing activities (59.6%), improving decision-making (56.5%), feeling safer (53.0%), sleeping better (52.3%), and coping with voices (45.3%). Patients with current paranoia and/or hallucinations had higher levels of the causal factors and of wanting these difficulties treated.
CONCLUSIONS: Patients with non-affective psychosis have high levels of treatable problems such as agoraphobic avoidance, worry, low self-esteem, and insomnia and they would like these difficulties treated. Successful treatment of these difficulties is also likely to decrease psychotic experiences such as paranoia.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31326234     DOI: 10.1016/j.schres.2019.07.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  20 in total

1.  Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS).

Authors:  R E Byrne; J C Bird; S Reeve; W Jones; D Shiers; A P Morrison; M Pyle; S Peters
Journal:  EClinicalMedicine       Date:  2020-07-07

2.  Clinicians' views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS).

Authors:  Byrne Re; Reeve S; Bird Jc; Jones W; Shiers D; Morrison Ap; Pyle M; Peters S
Journal:  EClinicalMedicine       Date:  2020-07-07

3.  Identifying effective characteristics of behavioral weight management interventions for people with serious mental illness: A systematic review with a qualitative comparative analysis.

Authors:  Charlotte Lee; Carmen Piernas; Cristina Stewart; Moscho Michalopoulou; Anisa Hajzadeh; Rhiannon Edwards; Paul Aveyard; Felicity Waite
Journal:  Obes Rev       Date:  2021-10-20       Impact factor: 10.867

4.  Virtual Reality Cognitive Therapy in Inpatient Psychiatric Wards: Protocol for a Qualitative Investigation of Staff and Patient Views Across Multiple National Health Service Sites.

Authors:  Poppy Brown; Felicity Waite; Sinéad Lambe; Laina Rosebrock; Daniel Freeman
Journal:  JMIR Res Protoc       Date:  2020-08-20

5.  Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange).

Authors:  Daniel Freeman; Ly-Mee Yu; Thomas Kabir; Jen Martin; Michael Craven; José Leal; Sinéad Lambe; Susan Brown; Anthony Morrison; Kate Chapman; Robert Dudley; Eileen O'Regan; Aitor Rovira; Andrew Goodsell; Laina Rosebrock; Aislinn Bergin; Tillie L Cryer; Dan Robotham; Humma Andleeb; John R Geddes; Chris Hollis; David M Clark; Felicity Waite
Journal:  BMJ Open       Date:  2019-08-27       Impact factor: 2.692

Review 6.  Sleep Abnormalities in Schizophrenia: State of the Art and Next Steps.

Authors:  Fabio Ferrarelli
Journal:  Am J Psychiatry       Date:  2021-03-17       Impact factor: 18.112

7.  Comparison of a theoretically driven cognitive therapy (the Feeling Safe Programme) with befriending for the treatment of persistent persecutory delusions: a parallel, single-blind, randomised controlled trial.

Authors:  Daniel Freeman; Richard Emsley; Rowan Diamond; Nicola Collett; Emily Bold; Eleanor Chadwick; Louise Isham; Jessica C Bird; Danielle Edwards; David Kingdon; Ray Fitzpatrick; Thomas Kabir; Felicity Waite
Journal:  Lancet Psychiatry       Date:  2021-07-08       Impact factor: 77.056

8.  Community Mental Health Care Delivery During the COVID-19 Pandemic: Practical Strategies for Improving Care for People with Serious Mental Illness.

Authors:  Sarah L Kopelovich; Maria Monroe-DeVita; Benjamin E Buck; Carolyn Brenner; Lorna Moser; L Fredrik Jarskog; Steve Harker; Lydia A Chwastiak
Journal:  Community Ment Health J       Date:  2020-06-19

Review 9.  Sleep and schizophrenia: From epiphenomenon to treatable causal target.

Authors:  Felicity Waite; Bryony Sheaves; Louise Isham; Sarah Reeve; Daniel Freeman
Journal:  Schizophr Res       Date:  2019-12-10       Impact factor: 4.939

10.  The weeks before 100 persecutory delusions: the presence of many potential contributory causal factors.

Authors:  Daniel Freeman; Anthony Morrison; Jessica C Bird; Eleanor Chadwick; Emily Bold; Kathryn M Taylor; Rowan Diamond; Nicola Collett; Emma Černis; Louise Isham; Rachel Lister; Miriam Kirkham; Ashley-Louise Teale; Eve Twivy; Felicity Waite
Journal:  BJPsych Open       Date:  2019-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.